About Us
- Home
- Grants and Recognitions
Grants and Recognitions
Pidnarulex
(CX-5461)
Silmitasertib
(CX-4945)
2021
Pidnarulex(CX-5461)
- Grant awarded by Ovarian Cancer Canada to support ovarian cancer trial
Silmitasertib(CX-4945)
- Multiple phase 2 clinical trials to treat COVID-19 patients financially supported by the top tier US hospitals-Banner Health
2020
Pidnarulex(CX-5461)
- Winner of Pfizer/PCF Global Challenge Awards
Pidnarulex(CX-5461)
- Combination with Talazoparib to treat prostate cancer
Silmitasertib(CX-4945)
- Named as potential Covid-19 therapy by the University of California San Francisco, Quantitative Biosciences Institute (QBI-UCSF) / The Institute for Antiviral Research, Utah State University ( IAR-USU) respectively and published in the scientific journal Cell
2019
Pidnarulex(CX-5461)
- Won the Excelsior Award issued by Institute for Biotechnology and Medicine Industry
2018
Silmitasertib(CX-4945)
- Grant awarded by US NIH-CTEP Program and collaborated with PBTC to study the drug in the treatment of Medulloblastoma (MB)
2017
Pidnarulex(CX-5461)
- Won the 14th National Innovation Award
2015
Pidnarulex(CX-5461)
- SU2C Breast Cancer Dream Team Drug Winner
Silmitasertib(CX-4945)
- Granted Orphan Drug Designation by the US FDA in Cholangiocarcioma
2013
Pidnarulex(CX-5461)
- Grant awarded by Peter MacCallum Cancer for the Haem cancer study